TRi-1 NEW
| Price | $67 | $96 | $147 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: TRi-1 | CAS No.: 246020-68-8 |
| Purity: 98.4% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | TRi-1 |
| Description | TRi-1 is irreversible inhibitor of cytosolic thioredoxin reductase 1 (TXNRD1), with an IC50 of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy |
| Animal Research | Fox Chase male SCID mice were treated once with TRi-1 (0.7 to 10 mg/kg) or TRi-2 (0.5 to 20 mg/kg) via intravenous injections, and mouse health status was observed for up to 72 hours. For repeateddose toxicity studies with tumor-bearing animals, mice were first inoculated with 1*10^6 FaDu cells in phosphate-buffered saline at a preshaved region located at the anterior lateral thoracic wall . After 13 days of growth, tumors were measured by calipers, and treatments were initiated. Mice were injected with TRi-1 (10 mg/kg), TRi-2 (15 mg/kg), auranofin (10 mg/kg), or vehicle a total of nine times during a 5-day span via intravenous tail injection. Upon the final day of dosing, injections were performed subcutaneously due to hematomas in several of the mice at the tail injection site. Mouse health status was monitored daily, weight was measured, and tumor volume was recorded from caliper measurements. |
| In vitro | TRi-1, impaired growth and viability of human tumor xenografts and syngeneic mouse tumors while having little mitochondrial toxicity and being better tolerated than auranofin. |
| In vivo | The anticancer efficacy of TRi-1 in mouse tumor models is consistent with the idea that TXNRD1 is important for cancer cell growth in vivo |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 62.5 mg/mL (190.13 mM) |
| Keywords | antitumor | inhibit | TRi 1 | Inhibitor | TRi-1 | FaDu | thioredoxin reductase 1 | glutathione | TRi1 | TXNRD1 |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Mitochondria-Targeted Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1KG |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2023-02-06 | |
| $170.00/5g |
VIP4Y
|
Shanghai UCHEM Inc.
|
2023-10-12 | |
| $0.00/25kg |
VIP5Y
|
Zhejiang Free Trade Zone Violet Trade Co., Ltd.
|
2024-03-18 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY